JPH0314512A - Oral cavity composition for suppressing deposition of dental plaque - Google Patents
Oral cavity composition for suppressing deposition of dental plaqueInfo
- Publication number
- JPH0314512A JPH0314512A JP14905889A JP14905889A JPH0314512A JP H0314512 A JPH0314512 A JP H0314512A JP 14905889 A JP14905889 A JP 14905889A JP 14905889 A JP14905889 A JP 14905889A JP H0314512 A JPH0314512 A JP H0314512A
- Authority
- JP
- Japan
- Prior art keywords
- oral cavity
- polymer
- dental plaque
- formula
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 208000002064 Dental Plaque Diseases 0.000 title claims abstract description 11
- 210000000214 mouth Anatomy 0.000 title abstract description 7
- 230000008021 deposition Effects 0.000 title abstract 2
- 229920000642 polymer Polymers 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims abstract description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 abstract description 12
- 239000000606 toothpaste Substances 0.000 abstract description 12
- 208000002925 dental caries Diseases 0.000 abstract description 6
- -1 monoethyl ester Chemical class 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 3
- 239000002324 mouth wash Substances 0.000 abstract description 3
- 229940051866 mouthwash Drugs 0.000 abstract description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004088 foaming agent Substances 0.000 abstract description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract description 2
- 239000011976 maleic acid Substances 0.000 abstract description 2
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 abstract description 2
- 239000003755 preservative agent Substances 0.000 abstract description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000080 wetting agent Substances 0.000 abstract description 2
- 239000000551 dentifrice Substances 0.000 abstract 2
- UVHQXWILFGUDTA-LNKPDPKZSA-N (z)-4-ethoxy-4-oxobut-2-enoic acid;methoxyethene Chemical compound COC=C.CCOC(=O)\C=C/C(O)=O UVHQXWILFGUDTA-LNKPDPKZSA-N 0.000 abstract 1
- 208000010266 Aggressive Periodontitis Diseases 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000019634 flavors Nutrition 0.000 abstract 1
- 201000006727 periodontosis Diseases 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000028169 periodontal disease Diseases 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000544066 Stevia Species 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000002272 anti-calculus Effects 0.000 description 1
- 229940090012 bentyl Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical group C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- REOJLIXKJWXUGB-UHFFFAOYSA-N mofebutazone Chemical group O=C1C(CCCC)C(=O)NN1C1=CC=CC=C1 REOJLIXKJWXUGB-UHFFFAOYSA-N 0.000 description 1
- ZWLPBLYKEWSWPD-UHFFFAOYSA-M o-toluate Chemical compound CC1=CC=CC=C1C([O-])=O ZWLPBLYKEWSWPD-UHFFFAOYSA-M 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000021058 soft food Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Abstract
Description
【発明の詳細な説明】
産業上の利用分野
本発明は歯垢の付着を抑制し、う蝕や歯周病を予防する
歯磨のような口腔用組底物に関する。DETAILED DESCRIPTION OF THE INVENTION Field of the Invention The present invention relates to an oral implant such as a toothpaste that suppresses the adhesion of dental plaque and prevents caries and periodontal disease.
従来の技術および課題
う蝕や歯周病は、口腔細菌の増殖により生じる歯垢か原
因で発症することか明らかにされている。Conventional techniques and problems It has been clarified that caries and periodontal disease are caused by dental plaque caused by the proliferation of oral bacteria.
すなわち、う蝕は歯垢中のストレプトコノカス・ミュー
タンス等のある種の細菌が糖を代謝して生じる酸が歯牙
のエナメル質を脱灰することによりひきおこされる。ま
た、歯垢中のある種の細菌は歯茎を刺激する酵素と内毒
素とを分泌し、歯茎に炎症をひきおこし、そのため歯茎
は出血しゃすくなり、弾力性を失い、歯から離れるよう
になり、歯周ボケノトを生じる。この歯周ボケノトが嫌
気性細菌の住処となり、それらの代謝物により歯周組織
が破壊され、歯周病がひきおこされる。That is, caries is caused by the acid produced when certain bacteria such as Streptoconoccus mutans in dental plaque metabolize sugar and demineralize tooth enamel. Also, certain bacteria in plaque secrete enzymes and endotoxins that irritate the gums, causing inflammation of the gums, which causes them to bleed easily, lose elasticity, and pull away from the teeth. This causes periodontal blur. This periodontal pocket becomes a home for anaerobic bacteria, and their metabolites destroy the periodontal tissue, causing periodontal disease.
そこで、従来から、う蝕や歯周病の予防のために歯垢の
付着を抑制する種々の方法や物質が提案されている。し
かしながら、十分に満足するものでは未だ見当たらない
。Therefore, various methods and substances have been proposed to suppress the adhesion of dental plaque in order to prevent dental caries and periodontal disease. However, nothing that is fully satisfactory has yet been found.
このような現状に鑑み、本発明者らは歯垢の付着抑制に
ついて種々検討したところ、意外にも、ある種のボリマ
ーが優れた歯垢付着抑制効果を有し、歯磨のような口腔
用組成物の歯垢付着抑制剤として有用であることを見出
した。In view of this current situation, the present inventors conducted various studies on suppressing the adhesion of dental plaque, and surprisingly found that certain polymers have an excellent effect of suppressing the adhesion of dental plaque, and that they can be used in oral compositions such as toothpaste. It has been found that it is useful as an agent for inhibiting plaque adhesion on objects.
ある種のポリマーを口腔用組戊物に処方することは従来
から知られており、例えば、米国特許第4,303,7
66号は、予め歯に適用された薬剤の歯からの溶出を防
止する膜形代用に分子量2000〜4,000,000
のポリアクリル酸フボリマーを処方した歯磨組戊物を開
示している。また、特開昭61−165317号は平均
分子量3,500〜7.500のポリアクリル酸ボリマ
ーあるいはコポリマーを抗歯石剤として口腔用組或物に
処方することを開示している。さらに、特開昭63−3
3321号はアクリル酸コボリマーを処方した口腔用組
戊物がフソ化物の歯エナメル質への吸収を促進すること
を開示している。It has been known for some time to formulate certain polymers into oral compositions, e.g., U.S. Pat. No. 4,303,7.
No. 66 is a film substitute with a molecular weight of 2000 to 4,000,000 that prevents the elution of a drug applied to the teeth from the teeth.
Discloses a toothpaste composition formulated with polyacrylic acid fuborimer. Furthermore, JP-A-61-165317 discloses the formulation of polyacrylic acid polymers or copolymers having an average molecular weight of 3,500 to 7,500 in oral cavity compositions as anti-calculus agents. Furthermore, JP-A-63-3
No. 3321 discloses that oral compositions formulated with acrylic acid cobolimers promote the absorption of fusodide into tooth enamel.
しかしながら、これらのボリマーは歯垢の付着を抑制す
るものではない。However, these polymers do not inhibit plaque adhesion.
課題を解決するための手段
本発明は、式:
[1]
E式中、R1およびR,は同一または異なって、各々、
炭素数1〜10の低級アルキル、nは平均分子量が50
,000〜5 0 0, 0 00となるような数を意
味する〕
で示される繰り返し単位を有するボリマーを歯垢付着抑
制剤として含有することを特徴とする歯垢付着抑制口腔
用組戊物を提供するものである。Means for Solving the Problems The present invention provides the formula: [1] E, in which R1 and R are the same or different, and each
Lower alkyl having 1 to 10 carbon atoms, n is an average molecular weight of 50
,000 to 500,000] A plaque adhesion inhibiting oral cavity composition characterized by containing a polymer having a repeating unit represented by the following as a plaque adhesion inhibitor. This is what we provide.
本発明で歯垢付着抑制剤として用いるコボリマーの式[
1〕で示される繰り返し単位におけるR,およびR,の
アルキルとしてはメチル、エチル、プロビル、ブチル、
ベンチル、ヘキシルなどが挙げられ、R1としては、特
に、メチルが好ましい。The formula of cobolimer used as a plaque adhesion inhibitor in the present invention [
In the repeating unit represented by 1], R and the alkyl of R include methyl, ethyl, proyl, butyl,
Bentyl, hexyl, etc. are mentioned, and R1 is particularly preferably methyl.
平均分子量は約50,000〜500,000程度のも
のが好ましい。式[1]の繰り返し単位を有するポリマ
ーの代表的なものとしてはR,がメチル、R2がエチル
、イソブロビルまたはブチルのちの、すなわち、ポリ(
メチルビニルエーテル/マレイン酸)のモノエチルー、
モノイソブロピルーまたはモノブチルエステルが挙げら
れ、これらは、各々、ガントレノツES−225、ES
−335、ES−425およびES−435の商品名で
知られるボリマーで、ガフ・ケミカルズ社(GAFCH
MICALS)より商業的に人手できる。これらのポワ
マーは歯垢付着抑制効果の観点から、一般に、口腔用組
戊物にたいして0.001〜10重量%の割合で処方さ
れる。The average molecular weight is preferably about 50,000 to 500,000. Typical examples of polymers having repeating units of formula [1] include R, methyl, R2, ethyl, isobrobyl, or butyl, that is, poly(
monoethyl of methyl vinyl ether/maleic acid),
monoisopropyl or monobutyl esters, which are Gantorenotsu ES-225, ES
-335, ES-425 and ES-435 are polymers manufactured by Gaff Chemicals (GAFCH).
MICALS) is more commercially available. These poamers are generally formulated in an amount of 0.001 to 10% by weight based on the oral cavity composition from the viewpoint of inhibiting plaque adhesion.
本発明の口腔用組戊物は公知の方注に従って練歯磨、粉
歯磨、1夜状歯磨、潤製歯磨、洗口剤などの剤形とする
ことができ、他の配合成分は特に限定するものではなく
、公知の研磨剤、湿潤剤、発泡剤、保存剤、香料、薬効
剤などが適宜処方できる。The oral composition of the present invention can be made into a dosage form such as a toothpaste, powdered toothpaste, overnight toothpaste, moisturized toothpaste, mouthwash, etc. according to known instructions, and other ingredients are not particularly limited. However, known abrasives, wetting agents, foaming agents, preservatives, fragrances, medicinal agents, etc. can be appropriately formulated.
実施例
つぎに実験例および実施例を挙げて本発明をさらに詳し
く説明する。EXAMPLES Next, the present invention will be explained in more detail with reference to experimental examples and examples.
実験例1
唾肢被覆ヒドロキノアパタイト(}{AP)ビーズ上へ
のストレブトコノカス・ミュータンス6715の吸着に
及ぼす効果
(1)20xtのHAPビーズをヒトの唾液(血液型○
)O.Eljとともに室温にて1時間インキユベートし
た。該ビーズを0.05M KCQ,lmM PO
.、lmM CaCILおよひ1mMMgCQ,から
なるpH6.0の緩衝l夜1ffl2で2回洗浄した。Experimental Example 1 Effect on adsorption of Strebutochonoccus mutans 6715 onto salivary limb-coated hydroquinoapatite (}{AP) beads (1) 20xt HAP beads were mixed with human saliva (blood type ○
)O. Incubated with Elj for 1 hour at room temperature. The beads were mixed with 0.05M KCQ, 1mM PO.
.. , 1 mM CaCIL and 1 mM MgCQ, pH 6.0 buffer, and washed twice with 1 ffl2.
(この緩衝液は、唾液無機成分に似せたものである)。(This buffer mimics the inorganic components of saliva).
次いで、室温にて、該ビーズをpH70の試料溶液o.
szcとともに1時間インキユベートシ、上記緩衝液1
村で2回洗浄した。The beads were then added to a pH 70 sample solution o.
Incubate for 1 hour with szc, buffer 1 above.
I washed it twice in the village.
次に、前記緩衝液0.5xI2中に[3H]チミジン標
識バクテリア(ストレプトコノカス・ミュータンス)を
5.OX10’個含むせ濁l夜を該ビーズに添加し、室
温にて1時間インキユベートした。前記緩衝液1村で3
回洗浄し、ビーズをバイアルに移し、液体シンチレーン
ヨンカウンターを用いて放射能を計副した。一方、既知
のc’H]t=識細胞の割合を同し方法で計数し、バク
テリア数の検量線を作戊した。Next, [3H]thymidine-labeled bacteria (Streptoconoccus mutans) was added to the buffer 0.5xI2 for 5 minutes. A suspension containing 10' OX was added to the beads and incubated for 1 hour at room temperature. 3 in 1 village of the buffer solution
After washing twice, the beads were transferred to a vial and radioactivity was counted using a liquid scintillation counter. On the other hand, the known c'H]t=percentage of sensitive cells was counted using the same method, and a calibration curve for the number of bacteria was created.
用いた試料溶液を第1表の唾液彼覆HAPの処理の欄に
示す。The sample solutions used are shown in the column of salivary HAP treatment in Table 1.
1%共重合体水溶液(ガントレソツES225)は、バ
クテリアの唾液被覆HAPへの吸着を著しく抑制したこ
とが確認された。It was confirmed that the 1% copolymer aqueous solution (Gantresotsu ES225) significantly suppressed the adsorption of bacteria to saliva-coated HAP.
実験例2
ビーグル犬での該ポリマーの歯垢抑制、歯肉炎抑制効果
20匹のビーグル犬の歯垢および歯石を完全に除去し、
4週間ソフトな飲食物を与えた。このうち10匹を第1
群とし、該ポリマーを含有しない蒸留水で以て処理し、
残りのl○匹を、第n群とし、ポリマー(ガントレッッ
ES−225)を含む水溶液で処理しγ二。この処理は
すべての歯へ5〜6ccの試料廖l夜を施用することに
より、1週間に5日、l日に1回行なつい、二重盲検法
を採用した。歯垢および歯肉炎はロー・アンド・シルネ
スの方広 (八eta Odontologica
Scandinavica, Q 1551〜55
5 (1963))によって評価した。Experimental Example 2 Plaque and gingivitis inhibiting effects of the polymer on beagle dogs Completely removed plaque and tartar from 20 beagle dogs.
They were fed soft food and drink for 4 weeks. 10 of these are the first
group and treated with distilled water not containing the polymer,
The remaining l○ rats were treated as the nth group and treated with an aqueous solution containing a polymer (Gantret ES-225). This treatment was carried out once a day, 5 days a week, by applying 5 to 6 cc of sample solution to all teeth, and a double-blind method was adopted. Plaque and gingivitis are treated with the help of low and sillness.
Scandinavica, Q 1551-55
5 (1963)).
結果を第2表に示す。The results are shown in Table 2.
巨 鰭 雫 笑 N −3− 窪 一 実施例1 つぎの処方に従い、常法により練歯磨を製造した。giant fin Shizuku lol N -3- Kubo 1 Example 1 A toothpaste was manufactured by a conventional method according to the following recipe.
戊 分 重量%
炭酸カルシウム 50ヒドロキシエ
チルセルロース l゛′/l/ e ・ ト
l 5グリセリン 10ラウリ
ル硫酸ナトリウム 0.5プルロニノク
1安息香酸ナトリウム
0 2サッカリンナトリウム
0.1ガントレノツES−225 1水
酸化ナトリウム 02香料
1
精製水 残部実施例2
つぎの処方に従い、常法により練歯磨を製造した。Weight % Calcium carbonate 50 hydroxyethyl cellulose l゛'/l/e・t
l 5 Glycerin 10 Sodium lauryl sulfate 0.5 Pluroninoc
1 Sodium benzoate
0 2 saccharin sodium
0.1 GANTRENOTS ES-225 1 Sodium hydroxide 02 Fragrance
1 Purified water Remainder Example 2 A toothpaste was manufactured by a conventional method according to the following recipe.
成分 重量%
第二リン酸カルシウム・二水和物 50無水ケイ酸
3ソルビット
20カルボキシメチルセルロース
1ラウロイルサルコシンナトリウム 05ポリ
オキシエチレン硬化ヒマン油 2バラ安息香酸メチ
ル 0.2ステビアエキス
0.2ガントレノツES−335
3酢酸トフフェロール 0.
5アラントイン 0.5香料
l精製水
残部実施例3
つぎの処方に従い、常法により液状歯磨を製造した。Ingredients Weight % Dicalcium phosphate dihydrate 50 silicic anhydride
3 sorbitol
20 carboxymethyl cellulose
1 Sodium lauroyl sarcosine 05 Polyoxyethylene hydrogenated human oil 2 Methyl benzoate 0.2 Stevia extract
0.2 Gun Torenotsu ES-335
Tophferol triacetate 0.
5 allantoin 0.5 fragrance l purified water
Remaining Example 3 A liquid toothpaste was manufactured by a conventional method according to the following recipe.
成分 重量%
グリセリン 35ブロビレングリ
コール 5ボリアクリル酸ナトリウム
3ラウリル硫酸ナトリウム 1
ボリオキ7エチレン硬化ヒマシ油 2サ/カリンナ
トリウム 0.2ガントレノッES−4
25 0.5水酸化ナトリウム
0.2香料 l
精製水 残部実施例4
つぎの処方に従い、常法により潤製歯磨を製造した。Ingredients Weight% Glycerin 35 Brobylene Glycol 5 Sodium polyacrylate
3 Sodium lauryl sulfate 1
Borioki 7 Ethylene Hydrogenated Castor Oil 2 Sa/Karin Sodium 0.2 Gantreno ES-4
25 0.5 Sodium hydroxide
0.2 fragrance 1 purified water remainder Example 4 According to the following formulation, a Junsei toothpaste was produced by a conventional method.
戊分 重盟%
炭酸カルンウム 70ヒドロキシエ
チルセルロース 1ソルビット
10グリセリン 1
5ラウリル硫酸ナトリウム l酢酸トコフ
ェロール 0.5フ,化ナトリウム
0・2パラオキシ安息香酸メチル
0.1サノカリンナトリウム
0.1ガントレノッES−435 0
.1香料 1
精製水 残部実施例5
つぎの処方に従い、常法により洗口剤を製造した。Bokubun Juumei% Carunium carbonate 70 Hydroxyethyl cellulose 1 Sorbit
10 glycerin 1
5 Sodium lauryl sulfate l Tocopherol acetate 0.5 Sodium lauryl sulfate
0.2 Methyl paraoxybenzoate
0.1 sanocalin sodium
0.1 GANTRENO ES-435 0
.. 1 fragrance 1 purified water remainder Example 5 A mouthwash was manufactured by a conventional method according to the following formulation.
戊分 重量%
グリセリン 10ボリオキシエチ
レン硬化ヒマシ油 1エタスール
15サッカリンナトリウム
0.2安息香酸ナトリウム 0.2ガ
ントレノッES−225 1水酸化ナト
リウム O、4香料
0.3
精製水 残部発明の効果
本発明によれば、歯垢の付着を効果的に抑制することの
できる、う蝕や歯周病に有用な口腔用組或物が得られる
。Bokubun Weight% Glycerin 10 Polyoxyethylene hydrogenated castor oil 1 Etasul
15 Saccharin sodium
0.2 Sodium benzoate 0.2 Gantrenot ES-225 1 Sodium hydroxide O, 4 Fragrance
0.3 Purified Water Residual Effects of the Invention According to the present invention, an oral cavity composition that can effectively suppress the adhesion of dental plaque and is useful for caries and periodontal disease is obtained.
Claims (1)
々、炭素数1〜10の低級アルキル、nは平均分子量が
50,000〜500,000となるような数を意味す
る] で示される繰り返し単位を有するポリマーを歯垢付着抑
制剤として含有することを特徴とする歯垢付着抑制口腔
用組成物。(1) Formula: ▲There are mathematical formulas, chemical formulas, tables, etc.▼ [In the formula, R_1 and R_2 are the same or different, each is a lower alkyl having 1 to 10 carbon atoms, n has an average molecular weight of 50,000 to 500, 000] A dental plaque adhesion-inhibiting oral composition characterized by containing a polymer having a repeating unit represented by the following as a dental plaque adhesion inhibitor.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1149058A JP2760573B2 (en) | 1989-06-12 | 1989-06-12 | Oral composition for inhibiting plaque adhesion |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1149058A JP2760573B2 (en) | 1989-06-12 | 1989-06-12 | Oral composition for inhibiting plaque adhesion |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0314512A true JPH0314512A (en) | 1991-01-23 |
JP2760573B2 JP2760573B2 (en) | 1998-06-04 |
Family
ID=15466751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1149058A Expired - Fee Related JP2760573B2 (en) | 1989-06-12 | 1989-06-12 | Oral composition for inhibiting plaque adhesion |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2760573B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05186321A (en) * | 1991-07-17 | 1993-07-27 | Unilever Nv | Oral composition containing phosphopeptide |
EP2868311A1 (en) * | 2013-10-30 | 2015-05-06 | Henkel AG&Co. KGAA | Oral and tooth care and cleaning agents for reducing the subsequent backstaining of teeth |
WO2015172922A1 (en) * | 2014-05-14 | 2015-11-19 | Henkel Ag & Co. Kgaa | Oral and dental hygiene and cleaning agents for reducing tooth discolouration |
KR20200093514A (en) | 2017-11-30 | 2020-08-05 | 라이온 가부시키가이샤 | Oral biofilm formation inhibitor and oral composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58208210A (en) * | 1982-03-24 | 1983-12-03 | コルゲ−ト・パ−モリブ・カンパニ− | Peroxydiphosphate blended dentifrice composition |
JPS6467412A (en) * | 1987-09-07 | 1989-03-14 | Toyota Motor Corp | Stabilizer control device |
-
1989
- 1989-06-12 JP JP1149058A patent/JP2760573B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58208210A (en) * | 1982-03-24 | 1983-12-03 | コルゲ−ト・パ−モリブ・カンパニ− | Peroxydiphosphate blended dentifrice composition |
JPS6467412A (en) * | 1987-09-07 | 1989-03-14 | Toyota Motor Corp | Stabilizer control device |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05186321A (en) * | 1991-07-17 | 1993-07-27 | Unilever Nv | Oral composition containing phosphopeptide |
EP2868311A1 (en) * | 2013-10-30 | 2015-05-06 | Henkel AG&Co. KGAA | Oral and tooth care and cleaning agents for reducing the subsequent backstaining of teeth |
WO2015172922A1 (en) * | 2014-05-14 | 2015-11-19 | Henkel Ag & Co. Kgaa | Oral and dental hygiene and cleaning agents for reducing tooth discolouration |
KR20200093514A (en) | 2017-11-30 | 2020-08-05 | 라이온 가부시키가이샤 | Oral biofilm formation inhibitor and oral composition |
Also Published As
Publication number | Publication date |
---|---|
JP2760573B2 (en) | 1998-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1272152A2 (en) | Use of chlorhexidine in the prevention of root caries | |
US4205061A (en) | Oral antimicrobial compositions | |
JPH09286712A (en) | Composition for oral cavity | |
US4559223A (en) | Silver sulfadiazine and/or zinc sulfadiazine-containing toothpaste or oral medicament | |
JP3022039B2 (en) | Oral composition for preventing tooth coloring | |
EP0976380B1 (en) | Method of recalcifying teeth | |
EP0562668A1 (en) | Monirritating antitartar and antiplaque oral compositions | |
JP2760573B2 (en) | Oral composition for inhibiting plaque adhesion | |
JPH07165544A (en) | Composition for oral cavity | |
JPS61200905A (en) | Composition for oral cavity application | |
JP3558138B2 (en) | Liquid oral composition | |
JP2812496B2 (en) | Antiplaque mouthwash | |
JPH07138139A (en) | Composition for oral cavity application | |
JP2866393B2 (en) | Oral composition for inhibiting plaque accumulation | |
JPH03178926A (en) | Composition for oral cavity application | |
JP3031785B2 (en) | Oral composition | |
JPH04300816A (en) | Composition for oral cavity | |
JPH0826953A (en) | Composition for oral cavity | |
SU715086A1 (en) | Toothpaste | |
US3819826A (en) | Composition and means for oral hygiene | |
JPH07165547A (en) | Composition for oral cavity | |
JPH04120014A (en) | Composition for oral cavity | |
JP2962530B2 (en) | Oral composition | |
JPH03178925A (en) | Composition for oral cavity application | |
JPS63130520A (en) | Composition for oral cavity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Cancellation because of no payment of annual fees |